The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development ... are urged to get Covid-19 shots each fall.

A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.

According to a press release issued by the NIH, the initiative will fund the institute's in-house development of universal ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...

Rudman Spergel, MD, director of clinical development at Moderna ... the technology to create one of the world’s first COVID-19 vaccines. In 2023, the company announced results from a phase ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...